Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 12
    records per page




    Gastrointestinal symptoms in coronavirus disease MESHD 2019: a cross-sectional study in Wuhan, China

    Authors: Yong Zhang; Zuneng Lu; Bo Wang; Jinxing Chang; Yonggang Ma

    doi:10.21203/rs.3.rs-69884/v1 Date: 2020-09-01 Source: ResearchSquare

    Background To investigate the clinical symptoms of coronavirus disease MESHD 2019 (COVID-19), particularly the prevalence SERO, time of symptom onset TRANS, and duration of gastrointestinal ( GI MESHD) symptoms.Methods This was a cross-sectional study using paper questionnaires. COVID-19 patients in a temporary hospital in Wuhan voluntarily completed surveys collecting data on COVID-19 symptoms and investigation results.Results A total of 212 adults TRANS were enrolled in this study, of whom 127 (59.9%) were female TRANS, mean age TRANS was 48.50 ± 13.15 years. Concerning symptoms, 78.8% (167/212) had fever HP fever MESHD, and 66% (140/212) had cough HP. Diarrhoea MESHD occurred in 43.8% (93/212) of patients. Nausea and vomiting HP Nausea and vomiting MESHD vomiting MESHD were also common (20.7%). Fever HP Fever MESHD and cough HP cough MESHD were frequently the initial symptoms of COVID-19, and they lasted for 5.00 [interquartile range (IQR): 3.00–10.00] days and 10.00 (IQR: 5.00–24.00) days, respectively. Most patients developed nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD 2.00 (IQR: 0–9.00) days and diarrhoea MESHD 5.00 (IQR: 0.25–11.00) days after the onset of initial symptoms, respectively. There was a median duration of 4.00 (IQR: 2.00–8.75) days with diarrhoea MESHD, and 6.00 (IQR: 4.00–10.00) days with nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD. The patients with diarrhoea MESHD were younger [45.85 ± 13.28 years vs 50.61 ± 12.82 years, P = 0.009] and were more likely to have an abnormal chest CT (95.7% vs 82.4%, P = 0.001) than those without diarrhoea MESHD.Conclusions In our cohort of patients, GI symptoms MESHD were common in COVID-19, occurred mostly during the middle stage of the disease, and lasted for a short duration. GI MESHD symptoms may not be associated with COVID-19 related treatment.

    A severe coronavirus disease MESHD 2019 patient with high-risk predisposing factors died from massive gastrointestinal bleeding MESHD: a case report

    Authors: Taojiang Chen; Qin Yang; Hongyu Duan

    doi:10.21203/rs.3.rs-45116/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: SARS-CoV-2 is highly infectious and has been a significant public health threat. Despite typical manifestations of illness are dominated by respiratory symptom, some patients have concurrent gastrointestinal manifestations, including   nausea MESHD, diarrhea HP diarrhea MESHD, and vomiting HP vomiting MESHD. Massive gastrointestinal bleeding MESHD, however, has rarely been reported. Case presentation: We herein describe a case of severe SARS-CoV-2 infected MESHD patient with several risk factors for poor prognosis, including male TRANS, hypertension HP hypertension MESHD, old age TRANS, mixed bacterial infection MESHD and multilobular infiltration on radiological imaging. After improvement of respiratory status, the onset of gastrointestinal bleeding MESHD occurred, probably resulting from direct viral invasion as evidenced by the positive findings for SARS-CoV-2 in the repeat stool specimens. Although aggressive resuscitation was administered, hematochezia HP hematochezia MESHD was uncontrolled. The patient rapidly deteriorated, suffered cardiac arrest HP cardiac arrest MESHD, and expired. Conclusions: Digestive symptoms could be severe in SARS-CoV-2 infected MESHD patients, especially for the high-risk individuals with predisposing conditions. A more thorough protocol for preventing cross-infection MESHD through faecal-oral transmission TRANS should be implemented in the process of patient care and infection MESHD control.

    Comparison of Clinical Features on Admission Between Coronavirus Disease MESHD 2019 and Influenza A among Children TRANS: A Retrospective Study in China

    Authors: Feng Liang; Xianfeng Wang; Hui Li; Jun Chen; Lei Liu; Jianbo Shao; Yi Xu; Liya He; Huiying Liang; Kuanrong Li; Sitang Gong; Huimin Xia

    doi:10.21203/rs.3.rs-44748/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) share similar symptoms with influenza A (IA), but it is more worthwhile to understand the disparities of the two infections regarding their clinical characteristics on admission. Methods: A total of 71 age TRANS-matched pediatric IA and COVID-19 patient pairs were formed and their clinical data on admission were compared. Results: Fever HP Fever MESHD, cough HP cough MESHD, nasal congestion and nausea/vomiting HP nausea/vomiting MESHD vomiting MESHD were the most common symptoms on admission for both infections MESHD but occurred less often in COVID-19. The IA patients were more likely to have lower-than-normal levels of lymphocyte count and percentage and to have higher-than-normal levels of activated partial thromboplastin time, prothrombin time, serum SERO C-reactive protein, and serum SERO procalcitonin, while the COVID-19 patients had higher odds of having lower-than-normal levels of neutrophil count and percentage.Conclusions: This study suggests that influenza A is more symptomatic than COVID-19 for children TRANS and might be an overall more severe infection HP at the time of admission. 

    Acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient: a case report

    Authors: Edoardo Mattone; Maria Sofia; Elena Schembari; Valentina Palumbo; Rosario Bonaccorso; Valentina Randazzo; Gaetano La Greca; Carmelo Iacobello; Domenico Russello; Saverio Latteri

    doi:10.21203/rs.3.rs-42230/v1 Date: 2020-07-13 Source: ResearchSquare

    Background coronavirus disease-19 (COVID-19) has spread to several countries around the world and has become an unprecedented pandemic. We report an extremely rare case of acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient.Case presentation: a COVID-19 patient was diagnosed with acute acalculous cholecystitis MESHD cholecystitis HP and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient’s clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous MESHD, the severe inflammation MESHD made surgery difficult to perform.Conclusions acalculous cholecystitis MESHD cholecystitis HP was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous MESHD histopathology pattern and the gallbladder wall ischemia MESHD was probably caused by vascular insufficiency MESHD secondary to severe acute respiratory distress syndrome MESHD respiratory distress HP syndrome of COVID-19 pneumonia MESHD pneumonia HP. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects MESHD small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and diarrhea HP diarrhea MESHD. Although the lack of evidence and guidelines about the management of patient with acute cholecystitis MESHD cholecystitis HP during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis MESHD cholecystitis HP on COVID-19 patients.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients):  fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from a meta-analysis across 13 countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v2 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians. Objective: The objective was to identify symptoms and their frequencies of COVID-19 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included in meta-analysis. Data abstraction and analysis: PRISMA guidelines, used for data abstraction and a table was generated by feeding it with numbers and proportions of each symptom described. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals were calculated.Results: Selected 14 studies, either cross-sectional or cohort studies are analyzed. There were 2,660 confirmed cases TRANS of COVID-19. The majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms identified from the meta-analysis and additional 7 symptoms were identified from reference searching. The most common symptoms were ( prevalence SERO >50%): fever HP fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5%): tonsil swelling MESHD, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD. Conclusion and implications of key findings: We found (25/32, from meta-analysis) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified is different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.  

    Differentiating coronavirus disease MESHD 2019 (COVID-19) from influenza and dengue

    Authors: Tun-Linn Thein; Li Wei Ang; Barnaby Edward Young; Mark IC Chen; Yee-Sin Leo; David Chien Lye

    doi:10.21203/rs.3.rs-36343/v1 Date: 2020-06-18 Source: ResearchSquare

    Background: The novel coronavirus disease MESHD 2019 (COVID-19) presents with non-specific clinical features. This may result in misdiagnosis or delayed diagnosis, and lead to further transmission TRANS in the community. We aimed to derive early predictors to differentiate COVID-19 from influenza and dengue.Methods: The study comprised 126 patients with COVID-19, 171 with influenza and 180 with dengue, who presented within 5 days of symptom onset TRANS. All cases were confirmed TRANS by reverse transcriptase polymerase chain reaction tests. We used logistic regression models to identify clinical characteristics and laboratory markers in classifying COVID-19 versus influenza, and COVID-19 versus dengue. The performance SERO of the models were evaluated using receiver operating characteristic curves (ROC).Results: Shortness of breath MESHD was the strongest predictor in the models for differentiating between COVID-19 and influenza, followed by diarrhoea MESHD. Higher lymphocyte count was predictive of COVID-19 versus influenza and versus dengue. In the model for differentiating between COVID-19 and dengue, patients with cough HP cough MESHD and higher platelet count were at increased odds of COVID-19, while headache HP headache MESHD, joint pain MESHD pain HP, skin rash HP skin rash MESHD and vomiting/nausea HP vomiting/nausea MESHD nausea MESHD were indicative of dengue. The area under the ROC was 0.92 for flu model and 0.99 for dengue model.Conclusion: Models based on clinical features and simple laboratory markers for differentiating COVID-19 from influenza and dengue, which possess good predictive performance SERO, can serve as a useful tool for primary care physicians to determine if further investigations or referrals would be required.

    COVID-19 may present with an itchy erythematous papular rash MESHD: a case report

    Authors: Alice Serafini; Peter K. Kurotschka; Mariabeatrice Bertolani; Silvia Riccomi

    doi:10.21203/rs.3.rs-27233/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: the most commonly reported clinical manifestations of Coronavirus Disease MESHD (COVID- 19) are: fever HP, fatigue HP fatigue MESHD, dry cough MESHD cough HP, anorexia HP anorexia MESHD, myalgias HP myalgias MESHD, dyspnoea MESHD and sputum production. Other, rarer, manifestations include headache HP headache MESHD, sore throat, rhinorrhoea, nausea HP nausea MESHD, diarrhoea and olfactory or taste disorders MESHD. Two recent small-scale studies suggest the possibility of a skin rash HP skin rash MESHD being a clinical presentation of the disease. The purpose of our case report is to bring attention to an atypical presentation of the disease ( skin rash HP skin rash MESHD) and reflect on the importance of the correct identification of COVID-19 suspicious symptoms as part of the crucial activity of case-finding in primary care.Case presentation: the patient is an Italian 32 years old female TRANS nurse who has had several close contacts TRANS to COVID-19 cases during her working shifts. On the 13 th March 2020 she developed an itchy erythematous papular rash MESHD sparing only her sparing only her face, scalp and abdomen. One week later she developed fever HP fever MESHD and diarrhoea MESHD. During the first week of remote assessment carried out by her General Practitioner (GP), she gradually developed a dry cough MESHD cough HP, intermittent fever HP fever MESHD and diarrhoea MESHD. At the time of article submission (31 days after the symptoms onset TRANS), she has not completely recovered and is still suffering of a dry cough MESHD cough HP, headache HP headache MESHD, fatigue HP fatigue MESHD and, occasionally, diarrhoea MESHD.Conclusions: this study suggest that skin manifestations could be an early presentation of COVID-19 and, during outbreaks, they should be taken into proper account by primary care providers as possibly caused by Sars-Cov-2. Early identification of COVID-19 patients is a crucial part of the strategy of case detection and case isolation, which has shown to be crucial in the reduction of incidence and COVID-19-related mortality. Further research is needed to establish frequency, symptoms, signs, pathogenesis and role in case detection of skin manifestations in COVID-19 patients.

    Neuroinvasive Potential of A Primary Respiratory Pathogen SARS-CoV2: Exploring the Underrecognized

    Authors: Durjoy Lahiri; Ritwick Mondal; Shramana Deb; Deebya Bandopadhyay; Gourav Shome; Sukanya Sarkar; Subhas C. Biswas

    id:10.20944/preprints202004.0382.v1 Date: 2020-04-21 Source: Preprints.org

    After the emergence of Severe Acute Respiratory Syndrome Coronavirus(SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV MESHD) in the last two decades, the world is facing its new challenge in SARS-CoV-2 pandemic with unfathomable global responses. The characteristic clinical symptoms for Coronavirus (COVID-19) affected patients are high fever HP, dry-cough, dyspnoea MESHD cough HP, dyspnoea, lethal pneumonia HP pneumonia MESHD whereas some patients also show few additional neurological signs such as headache HP headache MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD. The accumulative evidences suggest that Coronavirus is not only confined within the respiratory tract and that may also invade in central nervous system (CNS), peripheral nervous system (PNS) inducing some fatal Neurological diseases MESHD. Here we analyse the phylogenetic perspective of SARS-CoV2 with other strains of β-Coronaviridae from a standpoint of neurological spectrum disorders MESHD. Based on the existing case reports, literature and open data-bases, we also analyse the differential distribution of neurological impairments MESHD in COVID-19 positive patients along with angiotensin-converting enzyme-2(ACE2) expression dynamics in neuronal and non-neuronal tissue of central and peripheral nervous system. Besides, we discuss the need for modulations in clinical approach from a neurological point of view, as a measure towards reducing disease transmission TRANS, morbidity and mortality in SARS-CoV2 positive patients.

    Gastrointestinal symptoms characteristics of coronavirus disease MESHD 2019 patients: a cohort study

    Authors: Guoxin Huang; Shengduo Pei; Gaojing Qu; Xiaoyun Liu; Junwen Chen; Lisha Wang; Meiling Zhang; Bowen Tang; Shuai Yuan; Jinwei Ai; Haoming Zhu; Lei Chen; Yong Wang; Bin Pei

    doi:10.21203/rs.3.rs-22068/v1 Date: 2020-04-08 Source: ResearchSquare

    Backgroud: To describe the frequency and distribution characteristics of gastrointestinal symptoms of coronavirus disease MESHD 2019 (COVID-19) patients.Methods: As a cohort study, all confirmed COVID-19 patients with gastrointestinal symptoms MESHD at Xiangyang No.1 people’s hospital were included until February 21st, 2020. Course of disease no less than 21 days.Gastrointestinal symptoms relevant data were extracted and analyzed. The frequency histograms of the symptoms were plotted. Main symptom characteristics were summarized.Results: Of 50 included patients with gastrointestinal symptoms MESHD, 21 were male TRANS, 29were female TRANS. The mean age TRANS was 53 (SD 16) years. Course of disease ranged from 21 to 34 days with a median of 26 days. Among all patients, 16 were critically ill and five died, 12 discharged. Thirty-one clinical symptoms occurred 3168 times in total, 6 gastrointestinal symptoms MESHD occurred 439 (13.86%) times and 25 non-gastrointestinal symptoms occurred 2 729(86.14%) times. All symptoms and non-gastrointestinal symptoms distributed in 1 to 34 days, reached peak on 6th day of follow up, first seven days were the fastigium and decreasing in the rest days. Gastrointestinal symptoms mainly distributed in 1 to 34 days, reached a peak of 36 times per day on 6th of follow-up with a fastigium during 6 to 12 day, showed a trend of rise first and then fall HP. Nausea, vomit HP Nausea, vomit MESHD vomit MESHD and abdominal discomfort occurred 133, 70 and 62 times, respectively.Conclusions: A symptom frequency to time distribution model could describe the disease process quantitatively, indicating the change law of gastrointestinal symptoms MESHD and the organ damages in gastrointestinal system, could help us to better understand and treat the new disease. Females TRANS showed higher incidence of gastrointestinal symptoms MESHD, whether there is a sex difference in susceptibility needs to be further confirmed.Trial regitration: retrospectively registeredAuthors Guoxin Huang and Shengduo Pei contributed equally to this work. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.